WallStSmart

Femasys Inc (FEMY)vsIntuitive Surgical Inc (ISRG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Intuitive Surgical Inc generates 461335% more annual revenue ($10.58B vs $2.29M). ISRG leads profitability with a 28.1% profit margin vs 0.0%. ISRG earns a higher WallStSmart Score of 64/100 (C+).

FEMY

Hold

38

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 3/9Altman Z: -11.43

ISRG

Buy

64

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 6.0Quality: 7.8
Piotroski: 4/9Altman Z: 5.89
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for FEMY.

ISRGUndervalued (+77.9%)

Margin of Safety

+77.9%

Fair Value

$1896.32

Current Price

$422.06

$1474.26 discount

UndervaluedFair: $1896.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FEMY1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
39.9%10/10

Revenue surging 39.9% year-over-year

ISRG5 strengths · Avg: 9.2/10
Operating MarginProfitability
30.9%10/10

Strong operational efficiency at 30.9%

Altman Z-ScoreHealth
5.8910/10

Safe zone — low bankruptcy risk

Market CapQuality
$142.48B9/10

Large-cap with strong market position

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

Revenue GrowthGrowth
23.0%8/10

Revenue surging 23.0% year-over-year

Areas to Watch

FEMY4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$925,1803/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ISRG3 concerns · Avg: 3.3/10
PEG RatioValuation
2.164/10

Expensive relative to growth rate

Price/BookValuation
8.6x4/10

Trading at 8.6x book value

P/E RatioValuation
48.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : FEMY

The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 39.9% demonstrates continued momentum.

Bull Case : ISRG

The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.1% and operating margin at 30.9%. Revenue growth of 23.0% demonstrates continued momentum.

Bear Case : FEMY

The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.

Bear Case : ISRG

The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 48.8x leaves little room for execution misses.

Key Dynamics to Monitor

FEMY profiles as a hypergrowth stock while ISRG is a growth play — different risk/reward profiles.

ISRG carries more volatility with a beta of 1.51 — expect wider price swings.

FEMY is growing revenue faster at 39.9% — sustainability is the question.

ISRG generates stronger free cash flow (809M), providing more financial flexibility.

Bottom Line

ISRG scores higher overall (64/100 vs 38/100), backed by strong 28.1% margins and 23.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Femasys Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Femasys Inc. is an innovative medical technology company dedicated to transforming women's healthcare through its proprietary solutions for diagnosing and treating gynecological conditions. With a focus on non-surgical alternatives, Femasys is addressing prevalent issues such as uterine fibroids and contraception, positioning itself as a key player in the growing field of women’s health. As demand for minimally invasive treatments continues to rise, the company is strategically equipped to enhance patient outcomes and efficiency in healthcare delivery. By concentrating on significant unmet needs, Femasys aims to set new standards for care in this essential sector.

Intuitive Surgical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Want to dig deeper into these stocks?